Medexus targets $100M annual revenue for GRAFAPEX within 5 years post-launch
CEO Ken d'Entremont highlighted the successful FDA approval of GRAFAPEX, the branded name for treosulfan for injection in the U.S., which holds Orphan Drug Designation, ensuring at least seven years ...
Lipella Pharmaceuticals Inc.: Lipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for LP-310 in Oral Lichen Planus
Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company focused on developing innovative therapies ...
Belite Bio: The Picture Is Still Unclear
Belite Bio is a biotech firm specializing in innovative therapies for retinal degenerative eye diseases with high unmet needs ...
Beyond Air Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement
Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on harnessing ...